DexCom (DXCM)
(Delayed Data from NSDQ)
$69.00 USD
-0.70 (-1.00%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $68.91 -0.09 (-0.13%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$69.00 USD
-0.70 (-1.00%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $68.91 -0.09 (-0.13%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Zacks News
What Stocks Move After the Stimulus Bill Passes?
by John Blank
The U.S. economy can recover (quicker) with this bill.
US Government Reaches Deal on Stimulus Package: 5 Top Picks
by Nalak Das
The U.S. government and Senate reached an agreement to inject $2 trillion of stimulus to boost the U.S. economy amid the coronavirus-induced turmoil.
DexCom (DXCM) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, DexCom (DXCM) closed at $209.50, marking a +1.58% move from the previous day.
The Zacks Analyst Blog Highlights: HP, DexCom and Western Digital
by Zacks Equity Research
The Zacks Analyst Blog Highlights: HP, DexCom and Western Digital
No Gatherings of 50 People or More: Global Week Ahead
by John Blank
The struggle arrived from solving this riddle: It is the Travel & Leisure industry buckling completely that is more important than the Fed's surprise Sunday action.
New Strong Buy Stocks for March 16th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for today:
DexCom (DXCM) Down 3.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (DXCM) Outperforming Other Medical Stocks This Year?
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
DexCom (DXCM) Stock Moves -1.89%: What You Should Know
by Zacks Equity Research
In the latest trading session, DexCom (DXCM) closed at $247.64, marking a -1.89% move from the previous day.
Masimo Inks Deal With Imprivata, Improves Patient Monitoring
by Zacks Equity Research
Masimo's (MASI) partnership with Imprivata is likely to boost patient outcomes through the integration of Imprivata Medical Device Access into Masimo's Hospital Automation solutions.
Here's Why You Should Retain HMS Holdings (HMSY) Stock Now
by Zacks Equity Research
HMS Holdings (HMSY) is gaining traction from growing PI and TPM analytical services.
Here's Why You Should Invest in Intuitive Surgical Stock Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base. However, stiff competition remains a woe.
Here's Why You Should Hold on to OPKO Health Stock for Now
by Zacks Equity Research
OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and focus on R&D despite operating losses.
Here's Why You Should Invest in Integer Holdings Stock Now
by Zacks Equity Research
Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.
Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (DXCM) Outperforming Other Medical Stocks This Year?
Is Dexcom (DXCM) a Great Growth Stock?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Dexcom (DXCM).
Insulet Partners With Dexcom for Automated Insulin Delivery
by Zacks Equity Research
This agreement is a major step forward in Insulet's (PODD) commitment toward bolstering its automated insulin delivery system and providing better clinical outcomes for diabetes patients.
Increased Earnings Estimates Seen for DexCom (DXCM): Can It Move Higher?
by Zacks Equity Research
DexCom (DXCM) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Why DexCom (DXCM) Stock Might be a Great Pick
by Zacks Equity Research
DexCom (DXCM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Will DexCom Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in DexCom.
Can Dental Growth Drive Henry Schein's (HSIC) Q4 Earnings?
by Zacks Equity Research
Consistent contribution from Henry Schein One is likely to have benefited Henry Schein's (HSIC) Q4 performance.
DexCom (DXCM) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter earnings benefit from higher revenues and solid performing Sensor and Transmitter segments.
Baxter (BAX) and COSMED Receive FDA Clearance for Q-NRG+
by Zacks Equity Research
The latest FDA clearance is likely to boost Baxter's (BAX) Clinical Nutrition segment.
The Zacks Analyst Blog Highlights: Waste Management, TC Energy, Duke Energy, DexCom and Republic Services
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Waste Management, TC Energy, Duke Energy, DexCom and Republic Services